Physician

Muhammad Hamza Habib, M.D.

According to 2025 Medicare claims, Muhammad Habib, M.D. (NPI: 1518117902) practices hospice and palliative care in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (NPI: 1518904929; TIN: 223371727) and primary practice location at 08901-1914. Habib is affiliated with the RWJBH Accountable Care, LLC (ACO ID: A1247) and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Habib's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 140 traditional Medicare patients, billed 596 HCPCS/CPT codes, and received $56,845 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 1,360 prescription claims across 187 beneficiaries totaling $48,038 in drug costs, led by Celecoxib (Celecoxib). Open Payments data shows 2 records totaling $428. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $6,206 and ending at $56,845. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $53,954 and ending at $48,038. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	27	53	$6,206
2016	148	371	$42,787
2017	136	371	$42,064
2018	127	422	$45,766
2019	126	641	$70,196
2020	91	306	$27,571
2021	114	540	$65,869
2022	108	417	$45,451
2023	113	442	$48,119
2024	140	596	$56,845

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	163	547	$53,954
2016	112	648	$34,716
2017	144	956	$65,989
2018	158	887	$58,196
2019	180	1,382	$59,176
2020	112	722	$24,888
2021	141	848	$34,620
2022	135	834	$40,789
2023	142	1,042	$46,079
2024	187	1,360	$48,038

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	59	59	$148
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	108	354	$112
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	38	68	$75
G2212	Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or	25	35	$26
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	30	47	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Celecoxib	Celecoxib	142	5,003	$9,653
Xtampza Er	Oxycodone Myristate	11	330	$3,937
Fentanyl	Fentanyl	55	1,620	$3,820
Gabapentin	Gabapentin	179	8,986	$3,722
Oxycodone Hcl	Oxycodone Hcl	174	4,818	$2,568

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	2	$428	VERTEX PHARMACEUTICALS INCORPORATED
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad Hamza Habib, M.D.?

Tedicare shows public-source Medicare data for Muhammad Hamza Habib, M.D. (NPI 1518117902), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad Hamza Habib, M.D. have ACO affiliation data?

Muhammad Hamza Habib, M.D. is shown with ACO affiliation data for RWJBH Accountable Care, LLC (MSSP, ACO ID A1247) and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Muhammad Hamza Habib, M.D.?

Muhammad Hamza Habib, M.D. is linked to RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (billing NPI 1518904929) in the available physician profile data.

Does Muhammad Hamza Habib, M.D. have Open Payments data?

Muhammad Hamza Habib, M.D. has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.